A61K 31/573 - Composés contenant des systèmes cycliques du cyclopenta[a]hydrophénanthrène; Leurs dérivés, p.ex. stéroïdes substitués en position 17 bêta par une chaîne à deux atomes de carbone, p.ex. prégnane ou progestérone substitués en position 21, p.ex. cortisone, dexaméthasone, prednisone ou aldostérone
A61K 31/711 - Acides désoxyribonucléiques naturels, c. à d. contenant uniquement des 2'-désoxyriboses liés à l'adénine, la guanine, la cytosine ou la thymine et ayant des liaisons 3'-5' phosphodiester
A61K 31/715 - Polysaccharides, c. à d. ayant plus de cinq radicaux saccharide liés les uns aux autres par des liaisons glycosidiques; Leurs dérivés, p.ex. éthers, esters
The present invention provides compositions, pharmaceutical compositions and vaccines for the treatment, amelioration and / or prophylaxis of type II diabetes. The compositions, pharmaceutical compositions and vaccines of the invention comprise a virus-like particle of an RNA bacteriophage and an antigen, wherein said antigen comprises an interleukin-1 beta (IL-1β) mutein. When administered to an animal, preferably to a human, said compositions, pharmaceutical compositions, and vaccines induce efficient immune responses, in particular antibody responses, wherein typically and preferably said antibody responses are directed against IL-1β. Thus, the invention provides methods of treating, ameliorating or preventing type II diabetes by way of active immunization against IL-1β.
A61K 47/48 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p.ex. supports, additifs inertes l'ingrédient non actif étant chimiquement lié à l'ingrédient actif, p.ex. conjugués polymère-médicament
The present invention relates to a novel process for the production of a compound of formula (1), wherein n = 1 to 10 and m = 1 to 10, in linear two-step synthesis, wherein an N-maleimido acid NHS ester of formula (6), wherein n = 1 to 10, occurs as an intermediate. The invention further provides processes for the purification of the product and of the intermediate. In particular, the invention provides a process for the production and purification of succinimidyl-6-[β-maleimidopropionamido]hexanoate (SMPH). SMPH is a compound of formula (1), wherein m = 5 and n = 2.
C07D 403/12 - Composés hétérocycliques contenant plusieurs hétérocycles, comportant des atomes d'azote comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant deux hétérocycles liés par une chaîne contenant des hétéro-atomes comme chaînons
C07D 207/452 - Composés hétérocycliques contenant des cycles à cinq chaînons, non condensés avec d'autres cycles, ne comportant qu'un atome d'azote comme unique hétéro-atome du cycle avec uniquement des atomes d'hydrogène ou de carbone liés directement à l'atome d'azote du cycle comportant trois liaisons doubles entre chaînons cycliques ou entre chaînons cycliques et chaînons non cycliques comportant deux atomes d'oxygène liés directement en positions 2 et 5 par une double liaison avec uniquement des atomes d'hydrogène ou des radicaux ne contenant que des atomes d'hydrogène et de carbone, liés directement aux autres atomes de carbone du cycle, p.ex. maléimide avec des radicaux hydrocarbonés, substitués par des hétéro-atomes, liés directement à l'atome d'azote du cycle
4.
INFLUENZA HEMAGGLUTININ COMPOSITIONS AND USES THEREOF
The present invention is in the fields of medicine, public health, immunology, molecular biology and virology. The invention provides compositions, vaccine compositions and pharmaceutical compositions for the treatment, amelioration and / or prevention of influenza. The compositions, vaccine compositions and pharmaceutical compositions of the invention comprise a virus-like particle of an RNA bacteriophage and at least one antigen, wherein said at least one antigen is an ectodomain of an influenza virus hemagglutinin protein or a fragment of said ectodomain of an influenza virus hemagglutinin protein. When administered to an animal, preferably to a human, said compositions, vaccine compositions and pharmaceutical compositions efficiently induce immune responses, in particular antibody responses, wherein typically and preferably said antibody responses are directed against influenza virus. Thus, the invention further provides methods of treating, ameliorating and / or preventing influenza virus infection.
A61K 47/48 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p.ex. supports, additifs inertes l'ingrédient non actif étant chimiquement lié à l'ingrédient actif, p.ex. conjugués polymère-médicament
A61P 39/00 - Agents protecteurs généraux ou antipoisons
The present invention relates to virus-like particles of bacteriophage φCb5 and to recombinant φCb5 proteins which are capable of forming virus-like particles. The virus-like particles according to the invention are useful as immunological carriers which can, for example, be linked to an antigen, e.g. by chemical coupling or by genetic fusion. Virus-like particles according to the invention are also useful for the delivery of immunostimulatory substances, e.g. of immunostimulatory nucleic acids, to the immune system. The invention further relates to compositions, vaccines and pharmaceutical compositions comprising the inventive virus-like particles, wherein said compositions, vaccines and pharmaceutical compositions are capable of inducing or enhancing an immune response. The compositions, vaccines and pharmaceutical compositions described herein can therefore be used as a medicament for the treatment of a disease, disorder or physiological condition.
The invention provides compositions, vaccine compositions and pharmaceutical compositions for the treatment, amelioration and / or prevention of dengue fever. The compositions, vaccine compositions and pharmaceutical compositions of the invention comprise a virus-like particle of an RNA bacteriophage and at least one antigen, wherein said at least one antigen is a dengue antigen. When administered to an animal, preferably to a human, said compositions, vaccine compositions and pharmaceutical compositions induce efficient immune responses, in particular antibody responses, wherein typically and preferably said antibody responses are directed against dengue virus, preferably against dengue virus of any one of serotypes 1 to 4. Thus, the invention further provides methods of treating, ameliorating and/or preventing dengue virus infection by way of active immunization against domain III of the dengue virus envelope protein E, or against antigenic fragments thereof.
C07K 14/18 - Togaviridae, p.ex. flavivirus, virus de la peste, virus de la fièvre jaune, virus de l'hépatite C, virus de l'encéphalite japonaise
C12N 7/04 - Inactivation ou atténuation; Production de parties élémentaires de virus
A61K 39/39 - Préparations médicinales contenant des antigènes ou des anticorps caractérisées par les additifs immunostimulants, p.ex. par les adjuvants chimiques
A61K 47/48 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p.ex. supports, additifs inertes l'ingrédient non actif étant chimiquement lié à l'ingrédient actif, p.ex. conjugués polymère-médicament
7.
USE OF INTERLEUKIN-1 CONJUGATES IN THE TREATMENT OF DIABETES
The invention provides compositions, pharmaceutical compositions and vaccines for the treatment, amelioration and / or prophylaxis of diabetes, preferably of type II diabetes. The compositions, pharmaceutical compositions and vaccines of the invention comprise a core particle and an antigen, wherein said antigen comprises an interleukin-1 (IL-I) molecule. When administered to an animal, preferably to a human, said compositions, pharmaceutical compositions, and vaccines induce efficient immune responses, in particular antibody responses, wherein typically and preferably said antibody responses are directed against IL-I. Thus, the invention provides methods of treating, ameliorating or preventing diabetes, preferably type II diabetes, by way of active immunization against IL-I.
The invention relates to the filed of protein purification from cell homogenates. Disclosed is a process for clarifying cell homogenates which allows the production of a cleared homogenate that is sufficiently clear to be filtrated through a sterile filter. The process of the invention is useful for the large scale production of proteins or protein complexes, preferably of therapeutic proteins or protein complexes, where sterile filtration of the cleared homogenate is required.
The present invention is in the fields of medicine, public health, immunology, molecular biology and virology. The invention provides composition comprising a virus-like particle (VLP) linked to at least one antigen, wherein said antigen is NGF antigen. The invention also provides a process for producing the composition. The compositions of this invention are useful in the production of vaccines, in particular, for the treatment of pain. Moreover, the compositions of the invention induce efficient immune responses, in particular antibody responses.
The invention relates to recombinantly produced human monoclonalantibodies which are specifically binding nicotine and to nucleic acids encoding the same.The invention further relates to the use of such antibodies in the treatment of nicotine addiction.
The present invention is in the fields of medicine, vaccine and pharmaceutical formulation. The invention provides formulations comprising an angiotensin-virus-like particle conjugate and a stabilizer, wherein said stabilizer comprises a non-reducing disaccharide and a non-ionic surfactant. The lyophilized formulations are stable after a long time of storage at room temperature.
This invention relates to the field of vaccination and treatment or prevention diseases. In particular this invention relates to the treatment or prevention of diseases by inducing hapten-specific antibodyresponses in a vaccinated subject. The invention further provides a method forprevention or treatment of a disease by inducing hapten-specific antibodiesin asubject comprising administering into said subject acomposition comprising a virus-like particle of an RNA bacteriophage and at least one hapten linked thereto.
A61K 39/385 - Haptènes ou antigènes, liés à des supports
A61K 47/48 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p.ex. supports, additifs inertes l'ingrédient non actif étant chimiquement lié à l'ingrédient actif, p.ex. conjugués polymère-médicament
A61P 25/30 - Médicaments pour le traitement des troubles du système nerveux des états d'abus ou de dépendance
The present invention is in the fields of medicine, public health, immunology, molecular biologyand virology. The invention provides composition comprising a virus-like particle (VLP) linked to atleast one antigen, wherein said antigen is CCR5 PNt domain comprising one looped peptidic structure. The invention also provides a process for producing the composition. The compositions ofthis invention are useful in the production of vaccines, in particular, for the prevention and treatment of HIV infection. Moreover, the compositions of the invention induce efficient immune responses, in particular antibody responses.
The invention relates to aprocess for purifying coat protein of an RNA bacteriophage, wherein said process comprises the steps of disassembling a virus-like particle of an RNA bacteriophage and subsequently purifying said coat protein. The process described herein is designed to be scaled up to produce up to 100 g coat protein and more per batch, and it allows the efficientremoval of RNA and host cell derived impurities, typically below the quantification level. The invention further relates to purified coat protein of RNA bacteriophages, wherein said purified coat protein typically comprises less than 0.5 쎽g RNA, less than 0.4 IU of endotoxin, less than 5 ng host cell protein, and less than 1.5 ng of host cell DNA per 100 쎽g of said coat protein.
The application provides a method of isolating a eukaryotic cell expressing an antibody o f desired specificity, preferably a monoclonal single chain antibody (scFv). The application further provides methods which allow to clone the variable regions of said antibody fro m that isolated eukaryotic cell and to recombinantly produce antibodies comprising said variable regions as fusion protein with a purification tag, eg. as Fc-fusion, as a Fab fragment, or as whole antibodies, such as IgG, IgE, IgD, IgA and IgM. Said methods also allows to recombinantly produce antibodies with desired specificity in a fully species specific form, preferably as fully human antibodies.
The present invention is related to the fields of molecular biology, virology, immunology and medicine. The invention provides a composition comprising an ordered and repetitive antigen array, wherein the antigen is an IL-1 mutein. More specifically, the invention provides a composition comprising a virus-like particle, and at least one IL-1 mutein linked thereto. The invention also provides a process for producing the composition. The compositions of the invention are useful in the production of vaccines for the treatment of inflammatory diseases, and chronic autoimmune diseases, genetic diseases and cardiovascular diseases. The composition of the invention efficiently induces immune responses, in particular antibody responses. Furthermore, the compositions of the invention are particularly useful to efficiently induce self-specific immune responses within the indicated context.
The invention provides processes for the producing compositions comprising (i) a virus-like particle, wherein said virus-like particle is a virus-like particle of an RNA bacteriophage, and (ii) an oligonucleotide, wherein said oligonucleotide is packaged into said virus-like particle. The invention further provides processes for producing nucleotide compositions comprising oligonucleotides suitable to be used in the processes mentioned before. The invention further provides nucleotide compositions obtainable by the processes of the invention and uses thereof. The invention further provides compositions comprising (i) a virus-like particle, wherein said virus-like particle is a virus-like particle of an RNA bacteriophage, and (ii) an oligonucleotide, wherein said oligonucleotide is packaged into said virus-like particle, wherein said compositions are obtainable by the processes of the invention and wherein said compositions preferably comprises a purity of at least 98 %, most preferably of at least 99 %.
C07H 21/00 - Composés contenant au moins deux unités mononucléotide comportant chacune des groupes phosphate ou polyphosphate distincts liés aux radicaux saccharide des groupes nucléoside, p.ex. acides nucléiques
C12N 7/04 - Inactivation ou atténuation; Production de parties élémentaires de virus
C12N 15/11 - Fragments d'ADN ou d'ARN; Leurs formes modifiées
The present invention is in the fields of medicine, public health, vaccine and drug formulation. The invention provides composition formulat ions comprising a nicotine- carrier conjugate and a stabilizer, wherein said stabilizer comprises a non-reducing disaccharide and a non-ionic surfactant. The composition formulations are stable after a long time of storage at room temperature.
The application is related to compositions and methods for the treatment of hypersensitivity, wherein the compositions comprise a particle packaged with immunostimulatory nucleic acids. The compositions of the invention are particularly useful in the treatment of atopic eczema, asthma and IgE-mediated allergy (type I allergy), especially pollen allergy and house dust allergy.
A61P 37/00 - Médicaments pour le traitement des troubles immunologiques ou allergiques
A61K 39/39 - Préparations médicinales contenant des antigènes ou des anticorps caractérisées par les additifs immunostimulants, p.ex. par les adjuvants chimiques
A61K 47/48 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p.ex. supports, additifs inertes l'ingrédient non actif étant chimiquement lié à l'ingrédient actif, p.ex. conjugués polymère-médicament
The present invention is in the fields of medicine, public health, immunology, molecular biology and virology. The invention provides composition comprising a virus-like particle (VLP) linked to at least one antigen, wherein said antigen is HIV gpl60 peptide. The invention also provides a process for producing the composition. The compositions of this invention are useful in the production of vaccines, in particular, for the prevention and treatment of diseases. Moreover, the compositions of the invention induce efficient immune responses, in particular antibody responses.
The present invention is related to the fields of molecular biology, virology, immunology and medicine. The invention provides a composition comprising an ordered and repetitive antigen array, wherein the antigen is an IL-1 protein, an IL-1 mutein or an IL-1 fragment. More specifically, the invention provides a composition comprising a virus-like particle, and at least one IL-1 protein, IL-1 mutein or at least one IL-1 fragment linked thereto. The invention also provides a process for producing the composition. The compositions of the invention are useful in the production of vaccines for the treatment of inflammatory diseases, and chronic autoimmune diseases, genetic diseases and cardiovascular diseases. The composition of the invention efficiently induces immune responses, in particular antibody responses. Furthermore, the compositions of the invention are particularly useful to efficiently induce self-specific immune responses within the indicated context.
The invention provides a process for the purification recombinantly expressed, self- assembled VLP from the homogenate of a bacterial host, wherein the process can be scaled up to a commercial production scale in a cost effective manner. The process comprises a first chromatography using an anion exchange matrix, a second chromatography using hydroxyapatite and, optionally, a size exclusion chromatography. VLP preparations obtained by the process of the invention are essentially free of endotoxin contaminations.
The present invention is in the fields of medicine, public health, immunology, molecular biology and virology. The invention provides composition comprising a virus-like particle (VLP) linked to at least one antigen of the invention, wherein said antigen of the invention is CCR5 of the invention, gastrin of the invention, CXCR4 of the invention, CETP of the invention or C5a of the invention. The invention also provides a process for producing the composition. The compositions of this invention are useful in the production of vaccines, in particular, for the treatment of diseases in which the antigen of the invention mediates, or contributes to the condition, particularly for the treatment of AIDS, gastrointestinal cancers, coronary heart diseases or inflammatory diseases. Moreover, the compositions of the invention induce efficient immune responses, in particular antibody responses. Furthermore, the compositions of the invention are particularly useful to efficiently induce self-specific immune responses within the indicated context.
This invention provides a robust fermentation process for the expression of a capsid protein of a bacteriophage which is forming a VLP by self-assembly, wherein the process is scalable to a commercial production scale and wherein the expression rate of the capsid protein is controlled to obtain improved yield of soluble capsid protein. This is achieved by combining the advantages of fed-batch culture and of lactose induced expression systems with specific process parameters providing improved repression of the promoter during the growth phase and high plasmid retention throughout the process.
The present invention is in the fields of medicine, public health, immunology, molecular biology and virology. The invention provides compositions comprising a virus-like particle (VLP) or a virus particle and at least one antigen, particularly at least one feline antigen, and more particularly at least one feline antigen that is a human allergen. In certain embodiments, the antigen is a Fel d1 antigen or a fragment thereof, covalently linked to the VLP. The invention also provides methods for producing the compositions. The compositions of the invention induce efficient immune responses, in particular antibody responses, in mammals, particularly humans. The compositions and methods of the invention are useful in the production of vaccines, in particular for the treatment and/or prevention of allergies to cat dander and other cat antigens and allergens.
brevets